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BACKGROUND: Uterine cancer is the fourth leading cancer among US women. Changes in uterine cancer staging were made from
the American Joint Committee on Cancer (AJCC) 6th to 7th edition staging manuals, and 8 site-specific factors (SSFs) and 3 histo-
logic schemas were introduced. Carcinomas account for 95% of cases and are the focus of this report. METHODS: Distributions of
SSF values were examined for 11,601 cases of malignant cancer of the corpus uteri and uterus, NOS (not otherwise specified) diag-
nosed in Surveillance, Epidemiology, and End Results (SEER) Program registries during 2010. AJCC 6th and 7th edition staging distri-
butions were compared for 11,176 cases using data in both staging systems. AJCC 6th edition staging distributions during 2004-2010
were examined. AJCC 7th edition SSFs required by SEER were International Federation of Gynecology and Obstetrics stage (SSF1),
peritoneal cytology (SSF2), number of positive pelvic lymph nodes (SSF3), number of pelvic lymph nodes examined (SSF4), number
of positive para-aortic lymph nodes (SSF5), and number of para-aortic lymph nodes examined (SSF6). RESULTS: For SSFs related to
lymph nodes, a third of cases were classified as “not applicable,” reflecting that lymph node dissection is not indicated for cases with
stage1A and stage 4 diagnoses. AJCC 7th edition criteria assigned more cases to stage I (72.9%) than AJCC 6th edition criteria
(68.7%). Annual counts significantly increased during 2004-2010, as did counts for AJCC 6th edition stages INOS, IA, IB, IC, IIIA, IIIB,
IIIC, and IVB. The proportion of cases diagnosed with stage I cancer was stable, whereas stages II and IV decreased and stage III
increased. CONCLUSIONS: Five SSFs were suitable for analysis: peritoneal cytology results (SSF2), numbers of positive pelvic lymph
nodes (SSF3), pelvic lymph nodes examined (SSF4), positive para-aortic lymph nodes (SSF5), and para-aortic lymph nodes examined
(SSF6). Cancer 2014;120(23 suppl):3836-45. VC 2014 American Cancer Society.
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INTRODUCTION
Among cancers of the female genital system, corpus uteri and corpus, not otherwise specified (NOS) is the most com-
monly diagnosed cancer and the second most common cause of cancer death after ovarian cancer. Overall, uterine cancer
is the fourth most frequently diagnosed cancer among women in the United States, with 49,560 newly diagnosed cases
and 8190 deaths estimated to occur during 2013.1 Incidence rates historically have been slightly higher among white
women than black women and women of other races; however, the mortality rate among black women is almost twice
that of other women.2 Factors affecting racial variation include tumor aggressiveness and racial differences in the preva-
lence of hysterectomy.3,4 In recent years, the incidence rate of corpus uteri and corpus, NOS cancer has been increasing
among women of all major racial and ethnic groups. Estrogen unopposed by progesterone is a main risk factor for endo-
metrial cancer; and the increasing prevalence of obesity is thought to contribute to the recent increase in incidence.5 Dia-
betes and nulliparity are both risk factors that are increasing among US women.6,7 The majority of cancer cases of the
corpus uteri are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage I.8 Among more
aggressive histologies, such as clear cell adenocarcinoma and serous cancers, cases often present at a more advanced stage
and with worse prognosis. In these instances curative surgery may not be a treatment option.
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Surgical staging of uterine cancers involves removal of
the uterus, cervix, ovaries, and fallopian tubes and potentially
dissection of the pelvic and para-aortic lymph nodes.8 Biop-
sies are performed on areas of suspected metastases. Omen-
tectomy is typically is reserved for more aggressive histologic
subtypes. National Comprehensive Cancer Network guide-
lines for surgical management and use of lymphadenectomy
for staging of endometrial cancer give consideration to pre-
and intraoperative findings, extent of metastasis, and surgical
risk associated with comorbidities.9 Important prognostic
factors of endometrial cancer are stage, grade, and lymph
node positivity.10-12 For surgical staging of gynecologic can-
cers, many countries follow standards set by FIGO.13 The
7th edition of the American Joint Committee on Cancer
(AJCC) StagingManual, published in January 2010, includes
the same staging categories as the FIGO staging guidelines of
2008, except that the AJCC 7th edition does not include
IIICNOS or IVNOS. 14 Revisions in uterine cancer staging
in the AJCC 7th edition, compared with the AJCC 6th edi-
tion, include but are not restricted to reassigning stage IIA
cases to various subgroups of stage I and of some stage IIIA
cases to stage I and II subgroups. In addition, approximately
15% of unknown stage cases under the AJCC 6th edition
were reclassified to specific stages I, II, and II subcategories
under the AJCC 7th edition. Like changes in FIGO staging
guidelines, AJCC 7th edition revisions were made to
improve the prediction of prognosis.15,16 Additional changes
in the AJCC 7th edition include the collection of 8 site-
specific factors (SSFs), 6 of which were required by the Sur-
veillance, Epidemiology, and End Results (SEER) Program:
FIGO stage (SSF1), peritoneal cytology results (SSF2), num-
ber of positive pelvic lymph nodes (SSF3), number of pelvic
lymph nodes examined (SSF4), number of positive para-
aortic lymph nodes (SSF5), and number of para-aortic
lymph nodes examined (SSF6). Collection of data for the
other 2 SSFs, percentage of non–endometrioid cell type in
mixed histology tumors (SSF7) and omentectomy (SSF8)
were deemed optional. Another change was the separation of
corpus uteri cancer cases into 3 separate histology-based stag-
ing schemas—carcinoma, sarcoma, and adenosarcoma. This
report is restricted to the predominant schema, uterine carci-
nomas. We examined AJCC 6th edition staging trends dur-
ing 2004-2010, the effect of the changes in staging criteria
between the AJCC 6th and 7th editions, and the complete-
ness of SSF data collected in 2010.
MATERIALS AND METHODS
Analytic Cohorts
The SEER November 2012 submission file was used for
all analyses. Cases resided in 18 SEER registries covering
28% of the US population (also called the SEER-18): San
Francisco (SF)–Oakland standard metropolitan statistical
area, Connecticut, Detroit (metropolitan), Hawaii, Iowa,
New Mexico, Seattle (Puget Sound), Utah, Atlanta (met-
ropolitan), San Jose–Monterey (SJM), Los Angeles,
Alaska Natives, rural Georgia, California excluding SF/
SJM/Los Angeles, Kentucky, Louisiana, New Jersey,
greater Georgia.
International Classification of Diseases for Oncology,
3rd Edition (ICD-O-3),17 defines cancers of the corpus
uteri by topography codes C54.0-54.3, 54.8, 54.9 and of
uterus, NOS by ICD-O-3 topography code C55.9. The
AJCC 7th edition classifies these cancers into 3 histologi-
cal schema. Among diagnoses during 2010, corpus carci-
noma (ICD-O-3 morphology codes 8000-8790, 8950,
8951, 8980-8981, 9700-9701) accounted for 11,821
cases (95.6%). An additional 478 cases (3.9%) were classi-
fied into the corpus sarcoma schema (ICD-O-3 morphol-
ogy codes 8800-8932, 8934-8941, 8959-8974, 8982-
9136, 9141-9582), and the remaining 60 cases (0.5%)
belonged in the corpus adenosarcoma schema (ICD-O-3
morphology code 8933).
This report of AJCC 7th edition variables was re-
stricted to malignant cancer cases belonging to the pre-
dominant schema, carcinomas of the corpus uteri. For the
purpose of examining SSFs, 11,601 cases diagnosed in
2010 were included in the analytic cohort (Table 1) after
103 in situ cases were excluded because the updated
FIGO staging system does not include this group, 113
cases were excluded because they were not microscopically
confirmed, and 4 cases were excluded because they were
diagnosed via autopsy or death certificate only.
The cohort for AJCC 6th and 7th edition staging
comparisons was restricted to 11,176 cases after 425 addi-
tional cases with histologies not specified in the AJCC 6th
TABLE 1. Exclusion Criteria for Corpus Uteri Analy-
ses, SEER, 2010 Cases
Exclusion Criteria
AJCC 6th and 7th
Edition Stage SSFs
Criteria 1 Criteria 2
In situ cases Yes (103)a Yes (103)
Autopsy or death certificate only cases Yes (34) Yes (34)
Non–microscopically confirmed cases Yes (83) Yes (83)
Histologies for which AJCC 6th and
7th edition stage is not defined
Yes (425) No
Code 988, blank for each SSF No Yes
Final sample size 11,176 11,601
Abbreviations: AJCC, American Joint Committee on Cancer; SEER, Surveil-
lance, Epidemiology, and End Results; SSFs, site-specific factors.
aNumbers in parentheses show number of cases that were excluded.
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edition were excluded (8980/3: carcinosarcoma, NOS,
411 cases; 8246/3: neuroendocrine carcinoma, 12 cases;
and 8981/3: carcinosarcoma, embryonal type, 2 cases).
Analyses of AJCC 6th edition staging trends included
60,204 cases with malignant corpus uteri and uterus,
NOS cancer diagnosed during 2004-2010.
Key Changes Between the AJCC 6th and 7th
Editions
The AJCC 7th edition includes in situ and preinvasive cases;
however, the recent edition of the FIGO guidelines does not
include in situ cases, and this report is restricted to malignant
cancers only, which account for more than 99% of all
reported cases. Research based on the AJCC 6th edition
guidelines showed that stage IA (tumors confined to the
endometrium) could not be distinguished reliably from stage
IB (tumors that invade less than one-half of the myome-
trium), and in the 7th edition, they were combined as stage
IA. Under the 7th edition, stage IB is reserved for tumors
that invade one-half or more of the myometrium,18 which
were classified as stage IC under the 6th edition. Involve-
ment in the endocervical glandular portion of the cervix was
considered stage IIA under the AJCC 6th edition guidelines
and is considered stage INOS, stage IA, or stage IB under the
7th edition. Involvement of the cervical stroma was classified
as stage IIB in the AJCC 6th edition and remains stage II in
the 7th edition.19 The presence of cancer in ascites or perito-
neal washings is downgraded from stage IIIA in the AJCC
6th edition to stages INOS, IA, IB, or II in the 7th edition
because reports have shown that positive peritoneal cytology
alone is not an independent prognostic factor if endometrial
cancer is limited to the uterus.20 In the AJCC 7th edition,
cases with pelvic and para-aortic lymph node involvement
were assigned to separate substages. Stage IIIC1 indicates
positive pelvic nodes, and stage IIIC2 indicates positive para-
aortic nodes with or without positive pelvic nodes, with the
latter finding carrying a worse prognosis.21,22 The emphasis
on examination of lymph nodes is reflected in College of
American Pathologists (CAP) guidelines.23 Severity also
varies by schema.24 Studies have shown that malignant cytol-
ogy is associated with a negative prognosis and a higher rate
of recurrent disease.25 The 7th edition no longer requires
peritoneal cytology for staging but continues to recommend
its collection as an SSF. This shift is likely to be related to an
increasing body of evidence supporting positive peritoneal
cytology as an adverse risk factor only if there is other evi-
dence of extrauterine disease.26
Data regarding uterine sarcomas are not fully pre-
sented in this study. Sarcomas have a propensity for hema-
togenous spread and metastases. They were therefore
placed in a separate schema from carcinomas in the AJCC
7th edition.11,27 Carcinosarcoma (formerly known as ma-
lignant mixed M€ullerian tumors) continue to be staged as
carcinomas. Adenosarcoma of the uterus is a rare mixed
neoplasm that includes both a benign epithelial compo-
nent and a malignant stromal element. These tumors typi-
cally are polypoid masses that arise from the uterine
fundus. Most adenosarcomas are diagnosed as stage I and
generally carry a good prognosis.24,28
Summary of SSFs
Of 8 AJCC 7th edition SSFs introduced in 2010 for cor-
pus uteri and corpus, NOS cancer (Table 2), 6 are
required by the SEER Program for carcinoma, sarcoma,
and adenosarcoma: FIGO stage (SSF1), peritoneal cytol-
ogy results (SSF2), number of positive pelvic lymph nodes
(SSF3), number of pelvic lymph nodes examined (SSF4),
number of positive para-aortic lymph nodes (SSF5), and
number of para-aortic lymph nodes examined (SSF6).
Collection of SSF7 (percentage of non–endometrioid cell
type in mixed histology tumors) and omentectomy
(SSF8) were recommended by the AJCC but are not
required by the SEER Program despite being included in
the CAP cancer checklists.23,24
TABLE 2. SSFs for Corpus Uteri Cancer for AJCC 7th Edition Staging
SSF Description CS Version Available for Analysis Required by SEER
1 FIGO Stage 2 ydx 20101 Yes
2 Peritoneal cytology 2 ydx 20101 Yesa
3 Number of positive pelvic lymph nodes 2 ydx 20101 Yes
4 Number of examined pelvic lymph nodes 2 ydx 20101 Yes
5 Number of positive para-aortic nodes 2 ydx 20101 Yes
6 Number of examined para-aortic nodes 2 ydx 20101 Yes
7 Percentage of non–endometrioid cell type in mixed histology tumors 2 ydx 20101 No
8 Omentectomy performed during first course of treatment 2 ydx 20101 No
Abbreviations: AJCC, American Joint Committee on Cancer; CS, Collaborative Stage; FIGO, International Federation of Gynecology and Obstetrics; SEER,
Surveillance, Epidemiology, and End Results; SSFs, site-specific factors; ydx, year of diagnosis.
a Required for compatibility with AJCC 6th edition staging.
Original Article
3838 Cancer December 1, 2014
Statistical Analysis
Database queries were performed with SEER*Stat v 8.0.2
(IMS, Calverton, MD). Annual percentage change in
counts and 95% confidence intervals based on regression
models were calculated using the SEER*Stat trend statistic
option. Tables were populated using the FREQ procedure
TABLE 3. Distribution of AJCC 6th and 7th Edition Staging System for Malignant Corpus Carcinoma, 2004-
2010, SEER-18
Case Counts
Stage 2004 2005 2006 2007 2008 2009 6th 2010 APC (95% CI) 7th 2010
Stage I
INOS 456 477 503 519 527 577 557 3.7b (2.4, 5.1) 631
IAa 1890 1929 1991 2023 2190 2382 2493 5.0b (3.6, 6.5) 6027
IBa 2874 2958 2999 3250 3210 3326 3247 2.4b (1.1, 3.7) 1482
IC 951 979 1033 1063 1127 1242 1369 6.2b (4.6, 7.9
Stage II 566
IINOS 131 115 99 91 119 115 164 3.7 (25.2, 13.4)
IIA 243 283 296 292 266 282 174 22.9 (210.8, 5.8)
IIB 310 308 360 391 394 400 365 3.9 (0.0, 7.9)
Stage III
IIINOS 12 5 12 16 11 16 20 11.5 (22.6, 27.7) 26
IIIA 389 421 432 484 510 623 594 8.3b (5.5, 11.2) 312
IIIB 74 72 55 77 77 97 133 11.1b (1.8, 21.3) 135
IIIC 544 584 665 672 701 768 797 6.4b (4.9, 7.9)
IIIC1 486
IIIC2 307
Stage IV
IVNOS 8 4 8 12 10 5 2 23.8 (228.3, 28.9)
IVA 69 63 73 66 63 67 77 1.2 (22.5, 5.0) 79
IVB 579 559 562 603 641 616 669 2.8b (1.0, 4.6) 669
Unknown 512 488 492 474 501 509 515 0.4 (21.1, 1.9) 456
Total 9042 9245 9580 10,033 10,347 11,025 11,279 3.9b (3.3, 4.5) 11,176
Percentage Distribution
Stage 2004 2005 2006 2007 2008 2009 6th 2010 7th 2010
Stage I
INOS 5.0 5.2 5.3 5.2 5.1 5.2 5.0 5.7
IAa 20.9 20.9 20.8 20.2 21.2 21.6 22.3 53.9
IBa 31.8 32.0 31.3 32.4 31.0 30.2 29.1 13.3
IC 10.5 10.6 10.8 10.6 10.9 11.3 12.3
Stage II 5.1
IINOS 1.5 1.2 1.0 0.9 1.2 1.0 1.5
IIA 2.7 3.1 3.1 2.9 2.6 2.6 1.6
IIB 3.4 3.3 3.8 3.9 3.8 3.6 3.3
Stage III
IIINOS 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.2
IIIA 4.3 4.6 4.5 4.8 4.9 5.7 5.3 2.8
IIIB 0.8 0.8 0.6 0.8 0.7 0.9 1.2 1.2
IIIC 6.0 6.3 6.9 6.7 6.8 7.0 7.1
IIIC1 4.4
IIIC2 2.8
Stage IV
IVNOS 0.1 0.0 0.1 0.1 0.1 0.1 0.0
IVA 0.8 0.7 0.8 0.7 0.6 0.6 0.7 0.7
IVB 6.4 6.1 5.9 6.0 6.2 5.6 6.0 6.0
Unknown 5.7 5.3 5.1 4.7 4.8 4.6 4.6 4.1
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Abbreviations: AJCC, American Joint Committee on Cancer; APC, annual percent change; CI, confidence interval; NOS, not otherwise specified; SEER, Sur-
veillance, Epidemiology, and End Results.
a Stages IA and IB were combined as stage IA in the AJCC 7th edition.
bP<.05.
Staging of Cancer of the Corpus Uteri/Jamison et al
Cancer December 1, 2014 3839
(SAS v 9.2, Cary, NC). Kappa statistics were calculated to
assess agreement between AJCC 6th and 7th edition stag-
ing using the AGREE option of the FREQ procedure
(SAS v 9.2, Cary, NC).
RESULTS
Cases
Trends in stage distributions for AJCC 6th edition
corpus carcinoma, 2004-2010
Among microscopically confirmed malignant corpus
carcinoma cases meeting AJCC 6th and AJCC 7th edi-
tion staging criteria, the number of cases diagnosed
with malignant corpus carcinoma increased each year
from 2004 through 2010 (APC, 3.7; 95% CI, 3.3-4.5;
Table 3). Statistically significant increases in annual
counts were also observed in the annual number of
cases diagnosed at AJCC 6th edition stages INOS, IA,
IB, IC, IIIA, IIIB, IIIC and IVB. Despite the increase
in case counts, the annual percentage of stage I cases
remained at about 68% each year, with shifts from
substage IB to IA and IC (Fig. 1). The percentage of
stage II cases dropped from 7.6% in 2004 to 6.4% in
2010, primarily because of a decrease in cases classified
as stage IIA. The percentage of stage III cases increased
from 11.2% in 2004 to 13.8% in 2010, with small
increases in each substage. The percentage of cases
staged as “unknown” decreased from 5.7% in 2004 to
4.6% in 2010.
Comparison of AJCC 6th and 7th edition stage
distributions, corpus carcinoma, 2010
After exclusions, the AJCC stage comparison data set
included 11,176 cases (Table 4). A total of 431 cases were
moved from stages II and III according to AJCC 6th edi-
tion standards into stage I according to 7th edition crite-
ria. In particular, endocervical glandular involvement was
mapped to stage I in the 7th edition but not in the 6th
(66.5% vs 63.0%), and fewer cases were classified as stages
II or III in the 7th edition than in the 6th. Assessment of
ascites and/or peritoneal washings also ceased to be used
to define stage IIIA, resulting in fewer cases being classi-
fied as stage IIIA in the AJCC 7th edition compared with
the 6th edition. Minimal changes occurred between the
6th and 7th editions for stage IV. Although staging agree-
ment between the AJCC 6th and 7th editions is low
(44%) overall, this primarily reflects the structural
changes within stages I, II, and III.
SSFs
After exclusions, the SSF data set included 11,601 cases of
carcinomas of the corpus uteri diagnosed in 2010 accord-
ing to AJCC 7th edition criteria (Table 5). The majority
of these cases (68.3%) were diagnosed with endometrioid
adenocarcinoma (ICD-O-3 morphology code 8380),
with 46 other reported histologies (data not shown).
Table 5 lists not applicable and applicable codes for
analysis of the 6 SSFs. Applicable codes are further
Figure 1. Trends in stage distributions for AJCC 6th edition staging system for malignant corpus carcinoma, 2004-2010, SEER-18.
*Stages IA and IB were combined as stage IA in the AJCC 7th edition.
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stratified into known and unknown values. All cases are
“applicable” for FIGO Stage and Peritoneal Cytology
because data would be expected on each case. However,
the percentage of “not applicable” ranges from 37.3% to
64.1% for variables related to pelvic and para-aortic
lymph node involvement because lymph nodes are most
likely to be examined when biopsy or surgery is per-
formed. Cases coded as “not applicable” were excluded
from “known” versus “unknown” analyses for the SSFs.
SSF1: FIGO stage, corpus carcinoma
According to the Collaborative Stage (CS) Data Collection
System coding instructions, FIGO stage is recorded as it
was documented by the clinician or pathologist in the medi-
cal record. If it is not mentioned, an unknown value (999) is
assigned. Of the eligible corpus carcinoma cases diagnosed
in 2010, FIGO stage was known for 69.2% and unknown
for 30.8% of cases, with themajority of known cases in stage
I subgroups or stage II (Table 6). FIGO stage also can be
TABLE 4. Distribution of AJCC 6th by 7th Edition Staging System for Malignant Corpus Carcinoma, 2010,
SEER-18
Case Counts
Stage
AJCC 7
AJCC 6 INOS IA IB II IIINOS IIIA IIIB IIIC1 IIIC2 IVA IVB Unknown
INOS 557
IAa 2493
IBa 3247
IC 1369
IINOS 164
IIA 55 80 39
IIB 365
IIINOS 17 2 1
IIIA 16 177 64 35 302
IIIB 133
IIIC 483 304 10
IVNOS 2
IVA 77
IVB 669
Unknown 3 30 10 2 9 8 2 3 3 445
Total 631 6027 1482 566 26 312 135 486 307 79 669 456
Percentage Distribution
Stage
AJCC 7
AJCC 6 INOS IA IB II IIINOS IIIA IIIB IIIC1 IIIC2 IVA IVB Unknown
INOS 88.3
IAa 41.4
IBa 53.9
IC 92.4
IINOS 29.0
IIA 8.7 1.3 2.6
IIB 64.5
IIINOS 65.4 0.6 0.2
IIIA 2.5 2.9 4.3 6.2 96.8
IIIB 98.5
IIIC 99.4 99.0 2.2
IVNOS 2.5
IVA 97.5
IVB 100.0
Unknown 0.5 0.5 0.7 0.4 34.6 2.6 1.5 0.6 1.0 97.6
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Abbreviations: AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; SEER, Surveillance, Epidemiology, and End Results.
a Stages IA and IB were combined as stage IA in the AJCC 7th edition.
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derived from other stage data that are collected by the SEER
Program. A comparison of SSF1, the collected FIGO stage,
with AJCC 7th edition group stage found moderate agree-
ment between the two variables (kappa, 0.55).
SSF2: Peritoneal cytology, corpus carcinoma
The presence of cancer cells in ascites or peritoneal wash-
ings was a criterion for stage IIIA classification in the
AJCC 6th edition. Studies had shown that malignant cy-
tology was associated with a negative prognosis and a
higher rate of recurrent disease.25,26 Despite not being
part of the 2008 FIGO staging system, data were known
for 61.5% of corpus carcinoma cases. Table 7 indicates
that 54.2% of the 2010 cases had negative peritoneal cy-
tology, 7.2% had positive peritoneal cytology, and data
were unavailable for almost 38.7% of cases.
SSF3: Pelvic nodes positive
There were 4323 cases (37.3%) for whom SSF3 was not
applicable (Table 5). Of the 7278 cases with pelvic lymph
nodes assessed, 6966 (95.7%) had known values. Of these
7278 cases with pelvic lymph nodes assessed, 83.4% were
TABLE 5. Known and Unknown Values for Malignant Corpus Carcinoma SSFs, SEER, 2010 Cases
SSF
Not Applicable
Among Applicable
Known Unknown
Total
Codes n % Codes n % Codes n % n
1. FIGO Stage 888, 988 0 0.0 100-420 8025 69.2 987, 999 3576 30.8 11,601
2. Peritoneal cytologya 888, 988 0 0.0 000,010 7115 61.5 020, 997, 998, 999 4486 38.7 11,601
3. Number of positive pelvic nodes 098, 888, 988 4323 37.3 000-097 6966 95.7 999 312 4.3 7278
4. Number of examined pelvic nodes 000, 888, 988 4571 39.4 001-090 6372 90.6 095-098,999 658 9.4 7030
5. Number of positive para-aortic nodes 098, 988 6965 60.0 000-097 4268 92.1 999 368 7.9 4636
6. Number of examined para-aortic nodes 000, 988 7434 64.1 001-090 3354 80.5 095-098,999 813 19.5 4167
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; SEER, Surveillance, Epidemiology, and End Results; SSFs, site-specific factors.
a Required for staging.
TABLE 6. Distribution of SSF1: FIGO Stage for Ma-
lignant Corpus Carcinoma 2010, SEER
FIGO Stage CS Code Cases, n Frequency (%)
Total 11,601 100
I (NOS) 100 1658 14.3
1A 110 2897 25.0
1B 120 992 8.6
II 200 1046 9.0
III (NOS) 300 296 2.6
IIIA 310 299 2.6
IIIB 320 120 1.0
IIIC (NOS) 330 89 0.8
IIIC1 331 190 1.6
IIIC2 332 134 1.2
IV (NOS) 400 54 0.5
IVA 410 52 0.5
IV 420 198 1.7
Unknown 987, 999 3576 30.8
Abbreviations: CS, Collaborative Stage; FIGO, International Federation of
Gynecology and Obstetrics; NOS, not otherwise specified; SEER, Surveil-
lance, Epidemiology, and End Results; SSF, site-specific factor.
TABLE 7. Distribution of SSF2: Peritoneal Cytology
for Malignant Corpus Carcinoma, 2010, SEER
Result of Peritoneal
Cytology CS Code
Case
Count
Frequency
(%)
Total 11,601 100.0
Negative 0 6284 54.2
Positive, malignant
cells positive
10 831 7.2
Tested but undetermined,
unknown
20, 997-999 4486 38.7
Abbreviations: CS, Collaborative Stage; SEER, Surveillance, Epidemiology,
and End Results; SSF, site-specific factor.
TABLE 8. Distribution of SSF3: Number of Positive
Pelvic Lymph Nodes for Malignant Corpus Carci-
noma, 2010, SEER
Assessment of Pelvic
Lymph Nodes
Case
Count
Frequency
(%)
Total 7278 100.0
Nodes negative 6070 83.4
1 Positive node 348 4.8
2 Positive nodes 204 2.8
3 Positive nodes 106 1.5
4 Positive nodes 62 0.9
5 Positive nodes 30 0.4
6 or More positive nodes 112 1.5
Positive aspiration/core biopsy 7 0.1
Positive number unknown 27 0.4
Unknown 312 4.3
(Not Applicable) (4323)
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; SSF,
site-specific factor.
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classified as negative, 12.4% were classified as positive,
and the result of the assessment was classified as unknown
for 4.3% of the cases (Table 8).
SSF4: Pelvic nodes examined
SSF4 was not applicable for 4571 cases (39.4%); see Table
5. This variable was applicable to 7030 cases, and 6372
(90.6%) of them had known values. Among cases for
which pelvic nodes were examined, 40.3% were classified
as having between 1 and 10 nodes examined, and 33.9%
were classified as having had between 11 and 20 nodes
examined (Table 9). Analysis of the number of nodes
examined by grade showed that cases with poorly or un-
differentiated cancer were more likely to have dissected
pelvic nodes examined than those with moderately or
well-differentiated tumors (P< .001, data not shown).
SSF5: Para-aortic nodes positive
SSF was not applicable to 6965 cases (60%). The variable
was applicable to 4636 cases, and 4268 (92.1%) had
known values. Of the 4636 cases with para-aortic nodes
assessed (SSF 5), 82.7% were classified as having cancer-
negative nodes, 9.4% were classified as having positive
nodes, and the information was unknown for 7.9% of the
cases (Table 10).
SSF6: Para-aortic nodes examined
Regarding SSF6, para-aortic nodes were not examined in
64.1% of cases (Table 5). Among cases for which para-
aortic nodes were examined, 68.7% were found to have
had between 1 and 10 nodes examined, and 9.8% had
between 11 and 20 nodes examined (Table 11). Analysis
of the number of nodes examined by grade showed that
cases with poorly or undifferentiated cancer were more
likely to have had dissected para-aortic nodes examined
than those with moderately or well-differentiated tumors
(P< .001, data not shown).
DISCUSSION
In the 7th edition of the AJCC, SSFs were incorporated
for the first time, and extent of disease was expanded
beyond anatomic extent alone. This reflects new insights
regarding predictive and prognostically significant infor-
mation. Of the 6 SSFs that currently are collected by the
TABLE 9. Distribution of SSF4: Number of Pelvic
Lymph Nodes Examined for Malignant Corpus Car-
cinoma, 2010, SEER
Number of Pelvic Lymph
Nodes Examined
Case
Count
Frequency
(%)
Total 7030 100.0
1-10 2830 40.3
11-20 2382 33.9
21-30 810 11.5
31-89 350 5.0
901 0 0.0
No pelvic lymph node removed,
but aspiration of pelvic nodes
performed (95)
23 0.3
Pelvic lymph node removal, but number
of nodes unknown (96, 97, 98)
324 4.6
Unknown (999) 311 4.4
(Not applicable) (4571)
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; SSF,
site-specific factor.
TABLE 10. Distribution of SSF5, Number of Positive
Para-Aortic Lymph Nodes, Malignant Corpus Carci-
noma, 2010, SEER
Assessment of Para-Aortic
Lymph Nodes
Case
Count
Frequency
(%)
Total 4636 100.0
Nodes negative 3836 82.7
1-10 Nodes positive 373 8.1
11-20 Nodes positive 30 0.7
21-30 Nodes positive 2 0.0
31-89 Nodes positive 3 0.1
901 Nodes positive 0 0.0
Positive aspiration or core
biopsy of para-aortic
lymph node(s)
6 0.1
Positive para-aortic lymph
nodes, number not specified
18 0.4
Unknown 368 7.9
(Not applicable) (6965)
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; SSF,
site-specific factor.
TABLE 11. Distribution of SSF6, Number of Para-
Aortic Lymph Nodes Examined, Malignant Corpus
Carcinoma, 2010, SEER
Number of Para-Aortic Lymph
Nodes Examined
Case
Count
Frequency
(%)
Total 4167 100.0
1-10 2861 68.7
11-20 410 9.8
21-30 60 1.4
31-89 21 0.5
901 2 0.1
No para-aortic nodes removed, but
aspiration of para-aortic nodes
performed (95)
53 1.3
Para-aortic lymph node removal with
unknown number of nodes (96-98)
390 9.4
Unknown 370 8.9
(Not applicable) (7434)
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; SSF,
site-specific factor.
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SEER Program for corpus carcinoma, 5 appear to be suit-
able for analytic purposes, and we recommend that FIGO
staging be derived and no longer collected from the medi-
cal record. Staging differences between the AJCC 6th and
7th editions resulted in some downstaging of corpus carci-
noma. The quality of the lymph node data may reflect a
divergence between clinical practice and American Con-
gress of Obstetricians and Gynecologists (ACOG) and
FIGO guidelines. Specifically, despite the recommenda-
tions that all patients have lymph node dissections, SEER
data indicate that lymph nodes were more likely to be
biopsied when patients had poorly differentiated cancers.
Additional prognostic factors that could be considered as
SSFs for corpus uteri and corpus, NOS include lymph
vascular invasion.29
The ACOG guidelines state that retroperitoneal
lymph node assessment is a critical component of surgical
staging.9 Patients without lymph node involvement may
avoid adjuvant therapy and radiation. Both para-aortic
and pelvic lymph node beds should be evaluated because
retroperitoneal palpation is inaccurate and sentinel lymph
node biopsy or pelvic lymph node sampling alone is unac-
ceptable. Isolated para-aortic metastases are reported in
up to 17% of patients. Lymph nodes may not be sampled
when women with complex hyperplasia are diagnosed
with uterine corpus cancer without surgical staging. Obe-
sity also can impede access to the retroperitoneal space,
and prolonged surgery may not be indicated for patients
with severe comorbidities. Lymphedema, a chronic condi-
tion affecting a small percentage of women, also can influ-
ence decisions to perform a thorough lymph node
dissection during uterine cancer surgery.
Analysis of the number of nodes examined by grade
showed that cases with poorly or undifferentiated cancers
were more likely to undergo pelvic and para-aortic node
dissections than those with moderately or well-
differentiated cancers. This finding suggests that clinicians
are particularly likely to obtain this information when
patients have high-grade tumors.
Of the 3 uterine corpus cancer schemas, carcinomas
account for more than 95% of cases, with an annual inci-
dence rate approaching 25 per 100,000 women in 2010.2
Trends for all uterine corpus and corpus, NOS cancers
therefore mirror those for corpus carcinomas. Annual inci-
dence rates of sarcoma and adenosarcoma were lower, in the
range of 1 case per 100,000 women and 1 case per million
women, respectively. In all 3 schemas, a handful of histolo-
gies account for a large proportion of cases. For carcinoma,
the predominant histology was endometrioid carcinoma,
followed by adenocarcinoma, NOS. For sarcoma, leiomyo-
sarcoma, NOS was the main histology. Adenosarcoma was
the sole histology in the third schema. We are unaware of
major changes in ICD-O-3 codes for uterine corpus; how-
ever, subtle shifts in histologies are possible, and caution is
warranted when assessing temporal trends by schema. Limi-
tations include the collection of data in SEER registries
only. These registries cover only 28% of the United States,
and tend to have a higher proportion of foreign-born per-
sons than the general US population.
In summary, some downstaging occurred in conver-
sion from the AJCC 6th to the 7th edition.Most SSFs col-
lected by SEER are suitable for analysis. The paucity of
data on lymph nodes, with more responses among cases
with high-grade cancer, may reflect when lymph node dis-
sections are performed. Follow-up for survival can be used
to assess SSF predictive value.
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